Latest Enzo Biochem (ENZ) Headlines Enzo Bioche
Post# of 44
Enzo Biochem Reports Across the Board Second Quarter 2014 Improved Results
Business Wire - Tue Mar 11, 3:10PM CDT
Enzo Biochem Inc. (NYSE:ENZ) today reported across-the-board improved results for the fiscal second quarter ended January 31, 2014 as compared to the corresponding year-ago period.
Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results Wednesday, March 12, 2014 at 8:30 AM E.T.
Business Wire - Mon Mar 10, 1:28PM CDT
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2014 second quarter results, Wednesday, March 12, 2014, at 8:30 AM E.T.
2014 Analysis of the UK Hepatitis Diagnostics Market: Hospitals, Blood Banks, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
M2 - Mon Mar 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjsvbf/2014_analysis_of) has announced the addition of the "2014 Analysis of the UK Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures" report to their offering. The report presents a detailed analysis of the Hepatitis diagnostics market in the UK. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets: - Hospitals - Commercial/Private Labs - Blood Banks - Public Health Labs In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Companies Mentioned: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics/Grifols - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/rj...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Respiratory Diseases in the US 2014: Market Outlook and Emerging Opportunities
M2 - Fri Feb 21, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tw5kb/respiratory) has announced the addition of the "Respiratory Diseases in the US 2014: Market Outlook and Emerging Opportunities" report to their offering. This new 283-page report presents detailed analysis of the US Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals, Physician Offices, Commercial, and Public Health Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for microbiology testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products; and - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues.. Methodology - The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products. - In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as the author's proprietary data files was conducted. Companies Mentioned: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - BioRad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio - GenProbe - Hologic - ID Biomedical Innogenetics/Solvay - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics - OrthoClinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac - Wako For more information visit http://www.researchandmarkets.com/research/3t...espiratory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Automated Microbiology Market -- A Global Strategic Outlook: Molecular Diagnostics, Microbial Identification, Blood Culture, Urine Screening and Immunodiagnostics
M2 - Tue Feb 18, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/48jvmv/2014_automated) has announced the addition of the "2014 Automated Microbiology Market -- A Global Strategic Outlook: Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics" report to their offering. '2014 Automated Microbiology Market--A Global Strategic Outlook' is a new seven-country strategic analysis of the major business opportunities emerging in the automated microbiology market during the next five years. The report examines key trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, and country; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers. This comprehensive seven-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies. Worldwide Market Overview - Estimated universe of laboratories performing microbiology testing by country. - Specimen, test volume and sales forecasts by country. Market Segmentation Analysis - Sales and market shares for major suppliers by individual test and country. - Volume and sales forecasts for over 100 infectious disease assays by individual test and country. - Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy). - Review of the market dynamics, trends, structure, size, growth and major suppliers by country Companies Mentioned: - Abbott - Affymetrix - Agilent Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Caliper - Cepheid - Decode - Diadexus - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Hologic/Gen-Probe - Illumina - ID Biomedical/GSK - Kreatech - Li-Cor Biosciences - Life Technology - Lonza - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis Diagnostics/Grifols - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Sierra Molecular - Shimadzu - Takara Bio - Tecan - Thermo Fisher - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/48..._automated About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enzo Biochem's Clinical Lab and Nuclea Biotechnologies Join to Market New Test for Certain High Risk Breast Cancer Patients
Business Wire - Tue Feb 18, 8:00AM CST
--Collaboration Underscores Enzo's Commitment to Women's Health Diagnostics
Respiratory Diseases in the UK 2014: Market Outlook and Emerging Opportunities Available Now for Analysis
M2 - Mon Feb 17, 6:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/38644v/respiratory) has announced the addition of the "Respiratory Diseases in the UK 2014: Market Outlook and Emerging Opportunities" report to their offering. This new 281-page report presents detailed analysis of the UK Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals, Commercial and Public Health Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for microbiology testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products; and - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Methodology - The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products. - In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as the author's proprietary data files was conducted. Companies Mentioned: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - BioRad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio - GenProbe - Hologic - ID Biomedical Innogenetics/Solvay - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics - OrthoClinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac - Wako For more information visit http://www.researchandmarkets.com/research/38...espiratory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Analysis of the European Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts
M2 - Thu Feb 13, 3:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/8tlq3p/2014_analysis_of) has announced the addition of the "2014 Analysis of the European Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts " report to their offering. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides the five-year test volume and sales forecasts by country for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets: - Hospitals - Commercial/Private Labs - Blood Banks - Physician Offices - Public Health Labs For each country, in addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Key Topics Covered: I. Introduction II. Hepatitis Worldwide Market and Technology Overview III. France: Market Size, Growth and Major Suppliers' Sales and Market Shares IV. Germany: Market Size, Growth and Major Suppliers' Sales and Market Shares V, Italy: Market Size, Growth and Major Suppliers' Sales and Market Shares VI. Spain: Market Size, Growth and Major Suppliers' Sales and Market Shares VII. UK: Market Size, Growth and Major Suppliers' Sales and Market Shares X. Alternative Market Penetration Strategies XI. Potential Market Entry Barriers and Risks XII. Competitive Assessments Companies Mentioned: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/8t...nalysis_of
2014 Analysis of the US Hospital Cancer Diagnostics Market
M2 - Thu Feb 13, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/g5hk8t/2014_analysis_of) has announced the addition of the "2014 Analysis of the US Hospital Cancer Diagnostics Market" report to their offering. This new report contains 533 pages, 43 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: - Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. - Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. - Test volume and sales forecasts for 40 cancer diagnostic procedures performed in French hospitals. - Current instrumentation technologies and feature comparison of leading analyzers. - Sales and market shares of leading suppliers. - Emerging diagnostic technologies and their potential market applications. - Product development opportunities. - Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. - Business opportunities and strategic recommendations for suppliers. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And Market Needs D. Current and Emerging Technologies US A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Companies Mentioned: - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/g5...nalysis_of
2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities
M2 - Mon Feb 10, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/r66j8d/2014_analysis_of) has announced the addition of the "2014 Analysis of the World Cancer Diagnostic Testing Market: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities" report to their offering. This new report contains 1,200 pages, 450 tables and provides forecasts for 40 tumor markers by country and market segment, as well as sales and market shares for reagent and instrument suppliers. The report is available by region, country, section, market segment and individual test: Regions: Global, Europe Countries: France, Germany, Italy, Japan, Spain, UK, USA Sections: Assays, Competitors, Instrumentation, Technologies Market Segments: Hospitals (France, Germany, Italy, Japan, Spain, UK, USA), Personalized Testing Tests: AFP, Beta-2 Microglobulin,CA Tumor Markers, CEA, Cell Surface Markers, Occult Blood, PAP, Pap Smear/HPV, PSA To purchase a DataPack that includes (test volumes, sales forecasts, supplier shares) please E-mail us. Key Topics Covered: Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology B. Major Current And Emerging Cancer Diagnostic Tests C. Instrumentation Review And D. Current and Emerging Technologies Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biomedical Diagnostics - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila - bioMerieux For more information visit http://www.researchandmarkets.com/research/r6...nalysis_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Analysis of the French Infectious Disease Testing Market: Sales Forecasts, Supplier Shares, Competitive Strategies
M2 - Mon Feb 10, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jnmgt/2014_analysis_of) has announced the addition of the "2014 Analysis of the French Infectious Disease Testing Market: Sales Forecasts, Supplier Shares, Competitive Strategies" report to their offering. 2014 Opportunities in the French Infectious Disease Testing Market is a new strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key French market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, selorogy/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants. Rationale This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies. Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products. Key Topics Covered: I. Introduction II. Major Product Development Opportunities III. Design Criteria for Decentralized Testing Products IV. Alternative Market Penetration Strategies V. Potential Market Entry Barriers and Risks VI. Worldwide Overview of Major Tests, VII. France XI. Competitive Assessments - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Cepheid - DiaSorin - Diamedix - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wako - Wallac/PE - bioMerieux XVI. Appendix: Assumed Currency Exchange Rates For more information visit http://www.researchandmarkets.com/research/4j...nalysis_of
Sexually-Transmitted Diseases in the US 2014: Market Outlook and Emerging Opportunities
M2 - Thu Feb 06, 9:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/w3lgjw/sexuallytransmitt) has announced the addition of the "Sexually-Transmitted Diseases in the US 2014: Market Outlook and Emerging Opportunities" report to their offering. This new 280-page report presents detailed analysis of the US STD market, including sales forecasts and supplier shares for Chancroid, Chlamydia, Gonorrhea, Herpes (I/II, VI), Papillomavirus (Pap Smear, HPV), and Syphilis. The report provides test volume and sales projections for Hospitals, Commercial, Physician Offices, and Public Health Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for STD testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products; and - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Methodology The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products. In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as proprietary data files was conducted. Companies Mentioned: -Abbott -Affymetrix -Beckman Coulter/Danaher -Becton Dickinson -bioMerieux -BioRad -Cepheid -Diamedix -DiaSorin -Eiken Chemical -Enzo Biochem -Fujirebio -GenProbe -Hologic -ID Biomedical Innogenetics/Solvay -Kreatech -Life Technology -Lonza -Nanogen/Elitech -Novartis Diagnostics -OrthoClinical Diagnostics -Qiagen -Roche -Scienion -Sequenom -SeraCare -Siemens -Takara Bio -Thermo Fisher -Wallac -Wako For more information visit http://www.researchandmarkets.com/research/w3...ytransmitt About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 24, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
Baytex to Present at CIBC Whistler Institutional Investor Conference
Marketwire Canada - Wed Jan 15, 3:14PM CST
Baytex Energy Corp. (TSX:BTE)(NYSE:BTE) is pleased to announce that James Bowzer, President and Chief Executive Officer, will be presenting at the CIBC Whistler Institutional Investor Conference on Wednesday, January 22, 2014 at 4:00 pm PST (5:00 pm MST) in Whistler, British Columbia. Interested parties can listen to a live webcast and view the presentation slides via the following URL:
Niko Receives Conversion Notice
Marketwire - Thu Jan 09, 5:01PM CST
Niko Resources Ltd. (TSX: NKO) announces that on January 8, 2014, it received a notice of conversion in accordance with the terms of the amended and restated 7% senior unsecured notes due July 13, 2014 (the "Notes") to convert approximately US$0.25 million of the Notes. The conversion will result in the issuance of 120,904 common shares to a holder of the Notes and the outstanding principal balance of the Notes will be approximately US$8.3 million.
10-Q: E2OPEN INC
Edgar Online - Thu Jan 09, 4:29PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Orchid Island Capital Announces January 2014 Monthly Dividend and December 31, 2013 MBS Portfolio Characteristics
GlobeNewswire - Thu Jan 09, 4:27PM CST
-- January 2014 Monthly Dividend of $0.18 Per Share
Enzo Biochem Announces Upcoming Litigation Schedule
Business Wire - Tue Jan 07, 8:14AM CST
Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo", "the Company") today issued an update on its ongoing litigation surrounding the protection of its intellectual property and contractual rights. Two of the cases, in which Enzo is the Plaintiff, are scheduled for jury trials. Both cases will be tried in the United States District Court for the Southern District of New York in New York City.
Federal Court Awards Enzo Biochem over $61 Million in Patent Infringement Damages
Business Wire - Mon Jan 06, 9:39AM CST
Enzo Biochem Inc. (NYSE:ENZ) reported today that a Federal Court Judge in New Haven, CT, in connection with the favorable November 2012 jury finding of direct infringement damages of Enzo patents by Applera Corp., now Life Technologies Inc. (NASDAQ:LIFE), has awarded the Company prejudgment interest of $12,428,729, bringing the total award to in excess of $61 million. Additional post-interest on the full amount was also awarded starting November 7, 2012 until the total judgment is satisfied, which, it is estimated, could add several additional millions.